公开(公告)号：WO2006083673A3

公开(公告)日：2006-12-21

申请号：PCT/US2006002789

申请日：2006-01-24

Applicant: ABBOTT LAB ,  LIU GANG ,  SHAM HING L ,  SZCZEPANKIEWICZ BRUCE G ,  XIN ZHILI ,  ZHAO HONGYU ,  SERBY MICHAEL D ,  LIU BO ,  LIU MEI

Inventor： LIU GANG ,  SHAM HING L ,  SZCZEPANKIEWICZ BRUCE G ,  XIN ZHILI ,  ZHAO HONGYU ,  SERBY MICHAEL D ,  LIU BO ,  LIU MEI

IPC: C07D213/85 ,  A61K31/44 ,  A61P3/00 ,  A61P19/00 ,  A61P25/00 ,  C07D213/73 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D417/12

CPC classification number: C07D417/12 ,  C07D213/73 ,  C07D213/81 ,  C07D213/84 ,  C07D213/85 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D417/10

Abstract: The present invention relates to compounds of formula (I), that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

Abstract translation: 本发明涉及式（I）化合物，其为c-jun N-末端激酶1,2或3（JNK1，JNK2或JNK3）的抑制剂，含有该化合物的组合物和该化合物在 预防或治疗由JNK1，JNK2和JNK3激活调节的疾病。

公开(公告)号：ES2423668T3

公开(公告)日：2013-09-23

申请号：ES10720502

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  ABBVIE INC

Inventor： WELCH DENNIE S ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: Un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo,donde A está seleccionado entre el grupo que consiste en R1, R3, R4, y R5 están seleccionados independientemente entre el grupo que consiste en hidrógeno, alquenilo, alquilo, haloalquilo, G1, G2, -(CR4aR5a)m-G1, y -(CR4aR5a)m-G2; R4a y R5a, en cada caso, cada uno es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; G1, en cada caso, es independientemente arilo o heteroarilo, donde cada G1 está independientemente sin sustituir osustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo,halógeno, ciano, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)R2b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b,-C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-NO2,-N(Rb)S(O)2(R2b), -(CR4bR5b)m-OR1b, -C(OH)[(CR4bR5b)m-R4b]2, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)R2b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b),-(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)S(O)2(R2b),cianoalquilo, y haloalquilo.

公开(公告)号：NZ596827A

公开(公告)日：2014-01-31

申请号：NZ59682710

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： WELCH DENNIE S ,  SHEKHAR SHASHANK ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  RELO ANA-LUCIA ,  TURNER SEAN C ,  GANDARILLA JORGE ,  WILSON NOEL S ,  GASIECKI ALAN F ,  ZHANG MIN ,  DJURIC STEVAN W ,  ZHAO HONGYU ,  KRUGER ALBERT W ,  THOMPSON CHRISTINA M ,  LI HUANQIU

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D225/00 ,  C07D491/04 ,  C07D495/04

Abstract: 596827 Disclosed is a compound of formula (I), such as (3aS,10bS)-8-chloro-2-methyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo [3,4-c]azepin-6(10bH)-one and (3aS,10bS)-8-chloro-2-methyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo [3,4-c]azepin-6(10bH)-one, which is useful for treating disorders associated with 5HT receptors. Also disclosed is a process for making such compounds.

公开(公告)号：HK1168853A1

公开(公告)日：2013-01-11

申请号：HK12109595

申请日：2012-09-28

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： WELCH DENNIE S ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D20060101 ,  A61K20060101 ,  A61P20060101

公开(公告)号：MX2011012479A

公开(公告)日：2012-03-06

申请号：MX2011012479

申请日：2010-05-20

Applicant: ABBOTT LAB

Inventor： TURNER SEAN C ,  GASIECKI ALAN F ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  ZHANG MIN ,  DJURIC STEVAN W ,  GANDARILLA JORGE ,  SHEKHAR SHASHANK ,  WILSON NOEL S ,  RELO ANA-LUCIA ,  WELCH DENNIE S ,  KRUGER ALBERT W ,  ZHAO HONGYU ,  LI HUANQIU ,  THOMPSON CHRISTINA M

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: La presente solicitud se refiere a derivados de decahidropirroloazepina fusionada a arilo- y heteroarilo, octahidrooxepinopirrol, dióxido de octahidropirrolotiazepina, decahidrociclohepta[c]pirrol, y octahidrociclohepta[cjpirrol de fórmula (I) (ver fórmula (I)) en donde R1, R2, R3, R4, R5, A, Y1, Y2, e Y3 son como se define en la especificación. La presente solicitud también se refiere a composiciones que comprenden tales compuestos, procesos para hacer tales compuestos, y métodos para tratar condiciones de enfermedad utilizando tales compuestos y composiciones y métodos para identificar tales compuestos.

公开(公告)号：CA2761961A1

公开(公告)日：2010-11-25

申请号：CA2761961

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I), wherein R1,R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：CA2761961C

公开(公告)日：2017-10-24

申请号：CA2761961

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydroox-epinopyrrole, octahydropyrrolothiazepine dioxide, decahy-drocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyr-role derivatives of formula (I), wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：SG185672A1

公开(公告)日：2013-01-30

申请号：SG2012085346

申请日：2010-11-19

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：SG176100A1

公开(公告)日：2011-12-29

申请号：SG2011084357

申请日：2010-05-20

Applicant: ABBOTT LAB

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I), wherein R1,R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：AU2010353724A1

公开(公告)日：2012-12-20

申请号：AU2010353724

申请日：2010-11-19

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/55

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[